Trials / Completed
CompletedNCT01037985
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE AMELIORATION OF SCARRING OF THE SURGICAL INCISION IN SUBJECTS UNDERGOING AN ELECTIVE ABDOMINOPLASTY
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EXC 001 | Multiple intradermal injections of EXC 001 and placebo |
| DRUG | Placebo | Multiple intradermal injections of EXC 001 and placebo |
Timeline
- Start date
- 2009-12-03
- Primary completion
- 2010-07-07
- Completion
- 2010-09-22
- First posted
- 2009-12-23
- Last updated
- 2021-08-02
- Results posted
- 2021-08-02
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01037985. Inclusion in this directory is not an endorsement.